

# Index

## A

Adenylate cyclases, phosphorylation of, 306  
Adenylyl cyclases, 273–290  
  activity at single cell level, 290  
  overview, 273–275  
  phylogenetic tree, 276  
  physiological roles for  $\text{Ca}^{2+}$ -dependency of, 285–287  
  regulation by  $\text{Ca}^{2+}$ -signaling pathways, 278–290  
    by agonist-triggered  $\text{Ca}^{2+}$  release, 288  
    by  $\text{Ca}^{2+}$  entry, 287  
    compartments for  $\text{Ca}^{2+}$  and cAMP, 288–289  
    direct regulation by  $\text{Ca}^{2+}$ , 278–279  
    evidence for, 285, 286  
    indirect regulation by PKC, 281, 282–283  
    indirect regulation via CaMKII, CaMKIV, and CaN, 279–280, 282  
    indirect regulation via G $\beta\gamma$ , 283–285  
  regulatory susceptibilities of, 275–278  
  structural domains of, 275  
Aequorin, 361–362  
A kinase anchoring protein (AKAP), 9–11  
Anesthesia, IP<sub>3</sub>R activity and, 472  
Angiotensins, apoptosis regulation by, 446, 447  
Apoptosis, 443–452  
  ER stress and, 464–467  
  overview, 443–444  
  regulation by anti-apoptotic Bcl-2 family proteins, 449–451  
    IP<sub>3</sub> receptor interaction, 449–450  
    IP<sub>3</sub>R phosphorylation, 450  
    mitochondrial cross-talk, 450  
    regulation of luminal calcium, 450–451  
    regulation of prosurvival calcium signals, 451  
  regulation by antigen receptors, 444–445  
  regulation by pharmacological agents, 448  
    cisplatin, 448  
    staurosporine, 448  
    thapsigargin, 448  
  regulation by proapoptotic Bcl-2 family proteins, 451–452  
    calcium regulation by Bax and Bak, 451  
    calcium regulation by BH3-only proteins, 451–452  
  regulation by signaling molecules, 445–448  
    angiotensins, 446, 447  
    corticosteroids, 445–446

  nitric oxide, 447–448

  testosterone, 446–447

Arachidonate-regulated  $\text{Ca}^{2+}$  (ARC) channels, STIM1 roles in regulation, 74

Asthma, 474–475

Atherosclerosis, 472

ATP, ryanodine receptor (RyR) activation and, 105–106

ATPase. *See* Plasma membrane  $\text{Ca}^{2+}$  ATPase (PMCA); SERCA (sarco/endoplasmic reticulum  $\text{Ca}^{2+}$  ATPase); SPCA (secretory pathway  $\text{Ca}^{2+}$  ATPase)

Atypical periodic paralyses (APP), role of ryanodine receptors (RyRs) in, 101

Autophagy, 452–455

  induction by ER stress pathways, 453

  overview, 452–453

  regulation by calcium signaling, 453–454

  regulation by IP<sub>3</sub>Rs, 454–455

  T-cell activation, 454

Autosomal centronuclear myopathy, 475

Axon outgrowth and pathfinding, regulation of, 345–346

## B

Bak, calcium regulation by, 451

Bax, calcium regulation by, 451

Bcl-2 family proteins

  apoptosis regulation by anti-apoptotic, 449–451

  apoptosis regulation by proapoptotic, 451–452

  regulation of ER  $\text{Ca}^{2+}$  pump, 236

BH3-only proteins, calcium regulation by, 451–452

Bik, 452

Bim, 452

BiP (immunoglobulin bonding protein), 199–200

BK<sub>Ca</sub> channels, in smooth muscle, 436, 437

Brody disease, 475

Buffers. *See* Calcium ( $\text{Ca}^{2+}$ ) buffers, cytosolic; Calcium ( $\text{Ca}^{2+}$ ) buffers, organellar

Burn injury, 475

## C

$\text{Ca}^{2+}$  current types, 2–4

$\text{Ca}^{2+}$ -dependent inactivation (CDI), 68–69

$\text{Ca}^{2+}$  homeostasis, 188–191

## Index

- Ca<sup>2+</sup>-induced Ca<sup>2+</sup> release (CICR), in cardiac myocytes, 404–405, 407–409
- Ca<sup>2+</sup> sensors, as buffers, 177
- Cab45, 205
- CaBPs. *See* Calcium-binding proteins
- Cadmium toxicity, 475
- Calbindin-D9K (CB-D9K), 184–185
  - properties of, 178
  - structure, 181
- Calbindin-D28K (CB-D28K), 185–186
  - functional aspects, 185–186
  - properties of, 178
  - structural aspects, 185
  - structure, 181
- Calcineurin (CaN)
  - adenylyl cyclase regulation, 277, 282
  - cardiac RyRs and, 409
- Calcium-binding proteins
  - histidine-rich and regulation of ER Ca<sup>2+</sup> pump, 238
  - neuronal function, regulation of, 262–266
  - voltage-gated calcium channels
    - Ca<sub>v</sub>2 channels in synaptic transmission, 14–15
    - excitation-contraction coupling, 11
- Calcium (Ca<sup>2+</sup>) buffers, cytosolic, 177–191
  - Ca<sup>2+</sup> homeostasis and, 188–191
  - Ca<sup>2+</sup> sensors as, 177
  - calbindin-D9K (CB-D9K), 184–185
  - calbindin-D28K (CB-D28K), 185–186
    - functional aspects, 185–186
    - structural aspects, 185
  - calretinin, 186
  - defined, 177–179
  - mitochondrial Ca<sup>2+</sup> buffering compared, 187–188
  - parameters to characterize, 179–186
    - intracellular concentration, 179
    - ligand interaction, 182
    - metal-binding affinities, 179–180
    - metal-binding kinetics, 180, 182
    - mobility, 182
  - parvalbumins, 182–184
    - functional aspects, 183–184
    - structured aspects, 182–183
  - pH buffers compared, 178
  - properties of, 178
  - structure, 181
- Calcium (Ca<sup>2+</sup>) buffers, organellar, 197–207
  - endolysosomal compartment, 206
  - endoplasmic reticulum, 197–201
    - calreticulin, 198–199
    - ERp72, 200–201
    - GRP94, 200
    - immunoglobulin bonding protein (BiP/GRP78), 199–200
    - protein disulfide isomerase (PDI), 200
  - endoplasmic reticulum Golgi intermediate complex, 206
  - Golgi Ca<sup>2+</sup> stores, 205–206
  - mitochondria, 206
  - peroxisomes, 206
  - sarcoplasmic reticulum Ca<sup>2+</sup> stores, 201–205
- Calcium channels. *See* Store-operated calcium channels (SOCs); Transient receptor potential (TRP) channels; Voltage-gated calcium channels
- Calcium oscillations, 159–171
  - computational models for, 160–167
    - classifications, 162
    - InsP<sub>3</sub> oscillations and, 161–164
    - perspectives, 166–167
    - stochastic aspects, 164–165
  - interplay between Ca<sup>2+</sup> entry and Ca<sup>2+</sup> release during, 167–171
  - overview, 159–160
  - store-operated calcium (SOC) channels, 168–171
- Calcium signaling
  - autophagy regulation by, 453–454
  - in cardiac myocytes, 403–418
  - during mammalian fertilization, 313–328
  - in neuronal development, 337–348
  - in smooth muscle, 423–438
  - in synapse-to-nucleus communication, 371–392
  - visualization during embryonic skeletal muscle formation in vertebrates, 351–366
- Caldendrin, 265, 266
- Calmodulin (CaM)
  - Ca<sup>2+</sup> channels, 11, 14–15
  - IP<sub>3</sub> receptor regulation, 126
  - neuronal functions of, 255–257
  - ryanodine receptor (RyR) regulation, 106, 408
  - as sensor for CDI (Ca<sup>2+</sup>-dependent inactivation), 69, 407
- Calneurons, 263, 265–266
- Calnexin, regulation of ER Ca<sup>2+</sup> pump and, 236–237
- CALNUC (nucleobindin), 205
- Calreticulin
  - gain-of-function (overexpression), 199
  - loss-of-function (deficiency), 198–199
  - organellar calcium buffering, 198–199
  - regulation of ER Ca<sup>2+</sup> pump, 236–237
  - structure, 198
- Calretinin
  - properties of, 178
  - structural and functional aspects, 186
- Calsequestrin, 201–203
  - in cardiac myocytes, 408
  - ryanodine receptor (RyR) regulation, 106–107, 408
- Calumenin, regulation of ER Ca<sup>2+</sup> pump and, 237–238
- CaM. *See* Calmodulin (CaM)

- CaM kinase (CaMK)  
adenylyl cyclase regulation, 277, 279–280, 282  
CaMKII  
dendritic arborization and, 344–345  
ryanodine receptor (RyR) phosphorylation, 108  
CaN. *See* Calcineurin (CaN)  
Cancer, 476–477  
anticancer drugs, 476–477  
malignant transformation, 476  
Cardiac cycle, overview of, 403–404  
Cardiac myocytes  
adaptation to disease, 414–417  
calcium signaling, 403–418  
Ca<sup>2+</sup> efflux, 410–412  
contraction, 409–410  
excitation-contraction coupling, 404–406, 413  
L-type VOCCs, regulation of, 406–407  
RyRs and CICR, regulation of, 407–409  
cardiac cycle, 403–404  
subcellular organization, 412–414  
Cardiomyopathy, diabetic, 468–469  
Cardiovascular diseases, 472–473  
Catecholaminergic polymorphic ventricular tachycardia (CPVT), 408  
Cation channels, nonselective  
calcium signaling in smooth muscle, 429–431  
receptor-activated channels, 430–431  
CB-D9K. *See* Calbindin-D9K (CB-D9K)  
CB-D28K. *See* Calbindin-D9K (CB-D28K)  
CDI (Ca<sup>2+</sup>-dependent inactivation), 68–69  
Central core disease, 101, 475  
Channels. *See specific channel types*  
Cholestatic liver disease, 475  
Chronic heart failure, 472–473  
CICR (Ca<sup>2+</sup>-induced Ca<sup>2+</sup> release), in cardiac myocytes, 404–405, 407–409  
Cisplatin, apoptosis regulation by, 448  
Corticosteroids, apoptosis regulation by, 445–446  
CPVT (catecholaminergic polymorphic ventricular tachycardia), 408  
CRAC (Ca<sup>2+</sup> release-activated Ca<sup>2+</sup>) channels  
accumulation/activation at ER-PM junctions, 64–66  
overview, 58  
properties, 68–69  
Ca<sup>2+</sup>-dependent inactivation (CDI), 68–69  
ion selectivity and permeation, 68  
CSQ. *See* Calsequestrin  
Cytosolic calcium buffers, 177–191  
nephropathy, 470  
sensory neuropathy, 470  
vascular disease, 469–470  
Diacylglycerol kinases (DGK), phosphorylation of, 306  
Dihydropyridine receptors (DHPRs), 104  
  
**E**  
EF-hand proteins  
calcium-binding proteins (CaBPs), 262–264  
cytosolic calcium buffers, 177, 181  
neuronal calcium sensor (NCS) proteins, 257, 258  
Endolysosomal compartment  
calcium buffers, 206  
NAADP and physiology of, 152–153  
transient receptor potential (TRP) channels, 41–44  
Endoplasmic reticulum  
Ca<sup>2+</sup> homeostasis in, 462–464  
Ca<sup>2+</sup> pumps of, 229–245  
calcium buffers, 197–201  
calreticulin, 198–199  
ERp72, 200–201  
GRP94, 200  
immunoglobulin bonding protein (BiP/GRP78), 199–200  
protein disulfide isomerase (PDI), 200  
calcium depletion and disease, 461–477  
asthma, 474–475  
atherosclerosis, 472  
autosomal centronuclear myopathy, 475  
Brody disease, 475  
burn injury, 475  
cadmium toxicity, 475  
cancer, 476–477  
cardiovascular diseases, 472–473  
central core disease, 475  
chronic heart failure, 472–473  
diabetes mellitus, 467–471  
liver diseases, 475  
lung diseases, 474–475  
neural ischemia, 471  
neurodegeneration, 471–472  
neurological diseases, 471–472  
neuropathic pain, 472  
skeletal muscle diseases, 475  
skin disease, 475–476  
virus infection, 473–474  
conduit from synapse to nucleus, 390–391  
ER-PM junctions  
CRAR channel accumulation/activation at, 64–66  
formation and function of, 71–72  
STIM accumulation at, 63–64  
NAADP and lysosomal-ER interactions, 150–151  
transient receptor potential (TRP) channels, 38–41

## D

- Dendritic arborization, 344–345  
DHPRs (dihydropyridine receptors), 104  
Diabetes mellitus, 467–471  
cardiomyopathy, 468–469

## Index

- Endoplasmic reticulum Golgi intermediate complex (ERGIC), 206
- Endosomes, transient receptor potential (TRP) channels and, 41–44
- Epigenetic mechanisms in synaptic activity and  $\text{Ca}^{2+}$ -dependent transcriptional regulation, 385–387
- ER-assisted degradation, 464, 465
- ERGIC (endoplasmic reticulum Golgi intermediate complex), 206
- ERp57, regulation of ER  $\text{Ca}^{2+}$  pump and, 236–237
- ERp72, 200–201
- ER-PM junctions
- CRAR channel accumulation/activation at, 64–66
  - formation and function of, 71–72
  - STIM accumulation at, 63–64
- ER stress
- apoptosis and, 464–467
  - autophagy induction by, 453
- Excitation-contraction coupling
- in cardiac myocytes, 404–406, 413
  - voltage-gated calcium channels, 8–11
- Excitation-response coupling, voltage-gated calcium channels and, 8
- Excitation-secretion coupling, voltage-gated calcium channels and, 12
- Excitation-transcription coupling
- smooth muscle, calcium signaling in, 437
  - voltage-gated calcium channels, 11–12
- F**
- Fatty liver, nonalcoholic, 475
- Fertilization, mammalian
- $\text{Ca}^{2+}$  homeostasis in oocytes and eggs, 323–325
  - $[\text{Ca}^{2+}]_i$  clearing mechanisms, 323–324
  - $\text{Ca}^{2+}$  influx mechanisms, 324–325
  - $\text{Ca}^{2+}$  oscillations, molecular players responsible for, 318–327
  - calcium signaling, 313–328
  - egg activation, 314–318
  - $\text{IP}_3\text{R1}$  in maturing oocytes, 321–323
  - $\text{IP}_3\text{R1}$  in MII eggs, 319–321
  - $\text{PLC}\zeta$ , 325–327
- FK506-binding proteins (FKBPs)
- in cardiac myocytes, 408–409
  - ryanodine receptors (RyR) regulation, 107–108, 408–409
- Fluorescent  $\text{Ca}^{2+}$  reporters, 362–363
- G**
- G $\beta\gamma$ , adenylyl cyclase regulation by, 283–285
- GCAPs (guanylyl-cyclase-activating proteins), 261
- Glutamate. *See* Metabotropic glutamate receptor type 1 (mGluR1)
- Golgi apparatus
- $\text{Ca}^{2+}$  pumps of, 229–245
  - calcium buffers, 205–206
- G protein modulation, voltage-gated calcium channels and, 13–14
- G $_q$  proteins, 85
- GRP78, 199–200
- GRP94, 200
- Guanylyl-cyclase-activating proteins (GCAPs), 261
- H**
- Hailey-Hailey disease, 244
- Hax-1, regulation of ER  $\text{Ca}^{2+}$  pump, 236
- Heart failure, chronic, 472–473
- Histidine-rich  $\text{Ca}^{2+}$ -binding protein, 203, 238
- Hyperpolarizing-activated cyclic nucleotide-gated (HCN) channels, 404
- I**
- Immune cells, functional roles of STIM and Orai in, 70
- Immunoglobulin bonding protein (BiP), 199–200
- Inositol triphosphate ( $\text{IP}_3$ ), calcium oscillations and, 161–164
- Inositol triphosphate receptors. *See*  $\text{IP}_3$  receptors
- Intracellular  $\text{Ca}^{2+}$  dynamics, 107
- $\text{IP}_3$  receptors, 119–132
- autophagy regulation by, 454–455
  - Bcl-2 interaction, 449–450
  - calcium oscillation computational models, 162
  - calcium signaling in smooth muscle, 433–435
  - history of, 119–123
  - $\text{IP}_3\text{R1}$  in Purkinje cells, 85–86
  - phosphorylation, 450
  - regulation of, 123–127
  - structural determinants of activation, 127–132
  - virus infections and, 474
- Ischemia, neural, 471
- J**
- Junctate, 203, 205
- K**
- $\text{K}^+$  channel-interacting proteins (KChIPs), 261–262
- L**
- Liver diseases, 475
- Lung diseases, 474–475
- Lysosomes
- NAADP and lysosomal-ER interactions, 150–151
  - storage disease, 471
  - transient receptor potential (TRP) channels, 41–44

## M

- Malignant hyperthermia, role of ryanodine receptors (RyRs) in, 99–101
- Metabotropic glutamate receptor type 1 (mGluR1), 81–92
  - mechanisms of synaptic depolarizations, 86–91
  - overview, 81–83
  - postsynaptic  $\text{Ca}^{2+}$  release from internal stores, 83–86
  - TRPC channels and, 86–92
- Metal-binding affinities, of cytosolic  $\text{Ca}^{2+}$  buffers, 179–180
- Metal-binding kinetics, of cytosolic  $\text{Ca}^{2+}$  buffers, 180, 182
- $\text{Mg}^{2+}$ , ryanodine receptors (RyR) inhibition by, 105
- mGluR1. *See* Metabotropic glutamate receptor type 1 (mGluR1)
- Mitochondria
  - Bcl-2 and mitochondrial cross talk, 450
  - calcium buffers, 187–188, 206
- Multiminicore disease (MmD), role of ryanodine receptors (RyRs) in, 101
- Muscle. *See* Cardiac myocytes; Skeletal muscle; Smooth muscle

## N

- NAADP. *See* Nicotinic acid adenine nucleotide diphosphate (NAADP)
- NAADP receptors, 141–153
  - in endolysosomal physiology, 152–153
  - pharmacological properties, 146
  - two-pore channels, 147–148
- NCS. *See* Neuronal calcium sensor (NCS) family
- NCX. *See* Sodium/calcium exchanger (NCX)
- Nephropathy, diabetic, 470
- Neural ischemia, 471
- Neurodegeneration, 471–472
- Neurological diseases, 471–472
- Neuronal calcium sensor (NCS) family, 257–262
  - guanylyl-cyclase-activating proteins (GCAPs), 261
  - $\text{K}^+$  channel-interacting proteins (KChIPs), 261–262
  - KChIPs, 261–262
  - NCS-1, 257–259
  - recoverin, 259–261
- Neuronal development, calcium signaling in, 337–348
  - axon outgrowth and pathfinding, regulation of, 345–346
  - calcium-mediated specification of neurotransmitter phenotype, 340–344
  - dendritic arborization, 344–345
  - frequency coding by calcium transients, 347–348
  - ion channel expression, 346–347

- spatiotemporal characteristics of calcium transients, 339–340
- Neuronal function, regulation of, 253–266
  - calcium-binding proteins (CaBPs), 262–266
  - calmodulin, 255–257
  - neuronal calcium sensor (NCS) family, 257–262
  - synaptotagmins and neurotransmitter release, 254–255
- Neuropathic pain, 472
- Neuropathy, diabetic, 470
- Neurotransmitter phenotype, calcium-mediated specification of, 340
- Neurotransmitter release, synaptotagmins and, 254–255
- NHE (sodium/proton exchangers), phosphorylation of, 306
- Nicotinic acid adenine nucleotide diphosphate (NAADP). *See also* NAADP receptors
  - as  $\text{Ca}^{2+}$ -mobilizing messenger, 142–143
  - $\text{Ca}^{2+}$  stores targeted by, 143–144
    - mammalian cells, 144–146
    - sea urchin eggs, 143–144
  - desensitization of NAADP-evoked  $\text{Ca}^{2+}$  release, 144–146
  - discovery as  $\text{Ca}^{2+}$ -mobilizing molecule, 142
  - in endolysosomal physiology, 152–153
  - lysosomal-ER interactions, 150–152
  - plasma membrane excitability, modulation of, 152
  - structure and function, 142
- Nitric oxide, apoptosis regulation by, 447–448
- NMDA receptors
  - antagonism of synapse-to-nucleus communication, 381–382, 383
  - caldendrin and, 265
- Nuclear  $\text{Ca}^{2+}$  signaling, 382, 384–385, 388–390
- Nuclear pore permeability, calcium regulation of, 387

## O

- Oncomodulin, functional aspects of, 183
- Orai
  - calcium oscillations and, 168–169
  - calcium signaling in smooth muscle, 429
  - CDI ( $\text{Ca}^{2+}$ -dependent inactivation), participation in, 69
  - functional organization of, 62
  - functional roles of, 69–71
    - immune cells, 70
    - platelets, 70–71
    - skeletal muscle, 71
    - sweat glands and teeth, 71
  - molecular basis for store-operated calcium entry, 59–69
  - stoichiometry questions, 66–67
- Organellar calcium buffers, 197–207

## Index

### P

- P2X receptor, 430–431
- P54/NEFA, 205
- Parvalbumins, 182–184
  - functional aspects, 183–184
  - properties of, 178
  - structure, 181
  - structured aspects, 182–183
- PDI (protein disulfide isomerase), 200
- Peroxisomes, calcium buffers and, 206
- Phospholamban, regulation of ER Ca<sup>2+</sup> pump, 233–236
- Phospholipase C (PLC)
  - mGlu1-dependent slow EPSC (excitatory postsynaptic current) and, 87, 89–91
  - phosphorylation of, 305–306
  - PLC $\zeta$  in mammalian fertilization, 325–327
- Phospholipase D (PLD), phosphorylation of, 306
- PKA. *See* Protein kinase A (PKA)
- PKC. *See* Protein kinase C (PKC)
- Plasma membrane
  - ER-PM junctions
    - CRAR channel accumulation/activation at, 64–66
    - formation and function of, 71–72
    - STIM accumulation at, 63–64
  - NAADP and modulation of excitability, 152
- Plasma membrane Ca<sup>2+</sup> ATPase (PMCA)
  - genetic manipulations, 218–219
  - isoforms and tissue distribution, 216–218
  - overview, 213–215
  - protein kinase C (PKC) and, 304
  - role in physiology and pathology, 218
  - structural and regulatory characteristics, 215–216
- Platelets
  - functional roles of STIM and Orai in, 70–71
  - SERCA3 in, 239
- PLC. *See* Phospholipase C (PLC)
- PLD (phospholipase D), phosphorylation of, 306
- PMCA. *See* Plasma membrane Ca<sup>2+</sup> ATPase (PMCA)
- PMR1 mutants in yeast, 243
- Programmed cell death. *See* Apoptosis
- Protein disulfide isomerase (PDI), 200
- Protein kinase A (PKA)
  - ryanodine receptor (RyR) phosphorylation, 108, 409
  - sodium/calcium exchange (NCX) phosphorylation, 411
  - voltage-gated calcium channels, 406
- Protein kinase C (PKC), 295–308
  - activation of, 296, 298–304
  - adenylyl cyclase regulation, 277, 281, 282–283
  - imaging cPKC dynamics in living cells, 300–302
  - interaction between C2 domains and phospholipids, 299–300
  - overview of family, 295–296
  - properties of, 297

- regulation of Ca<sup>2+</sup> handling, 304–306
  - regulatory loops, 306–308
  - sodium/calcium exchange (NCX) phosphorylation, 411
  - terminating signaling, 302–304
  - voltage-gated calcium channels, 406
- Protein phosphatases, phosphorylation of, 306
- Purkinje cells
  - cytosolic Ca<sup>2+</sup> buffers, 189–191
  - metabotropic glutamate receptor type 1 (mGluR1), 82–92

### R

- Reactive nitrogen species, ryanodine receptors (RyR)
  - regulation, 108–109
- Reactive oxygen species, ryanodine receptors (RyR)
  - regulation, 108–109
- Recoverin, 259–261
- Ryanodine receptors (RyRs), 97–109
  - calcium oscillation computational models, 162
  - calcium signaling in cardiac myocytes, 407–409, 414, 415, 416
  - calcium signaling in smooth muscle, 432–433
  - calsequestrin interaction with, 201
  - expression of, 99
  - human diseases, roles in, 99–102
  - receptor genes and isoforms, 98–99
  - regulation, 104–109
    - Ca<sup>2+</sup>, Mg<sup>2+</sup>, and ATP, 105–106
    - calmodulin, 106, 408
    - calsequestrin, 106–107, 408
    - FK506-binding proteins, 107–108, 408–409
    - phosphorylation, 108, 409
    - reactive oxygen species and reactive nitrogen species, 108–109
    - voltage-gated calcium channels, 104–105
  - ultrastructural studies, 102–104
  - virus infections and, 474
- RyRs. *See* Ryanodine receptors (RyRs)

### S

- Salivary glands, abnormal Ca<sup>2+</sup> signaling in, 470–471
- Sarco/endoplasmic reticulum Ca<sup>2+</sup> ATPase. *See* SERCA (sarco/endoplasmic reticulum Ca<sup>2+</sup> ATPase)
- Sarcoplipin, regulation of ER Ca<sup>2+</sup> pump, 233–236
- Sarcoplasmic reticulum
  - Ca<sup>2+</sup> homeostasis in, 462–464
  - calcium buffers, 201–205
  - transient receptor potential (TRP) channels, 38–41
- Sea urchin eggs
  - NAADP-evoked Ca<sup>2+</sup> release, 143–144
  - properties of endogenous two-pore channels from, 148–149

- Second messengers, in synapse-to-nucleus communication, 378–381
- Secretory granules, transient receptor potential (TRP) channels and, 44
- Secretory pathway  $\text{Ca}^{2+}$  ATPase. *See* SPCA (secretory pathway  $\text{Ca}^{2+}$  ATPase)
- Secretory vesicles, transient receptor potential (TRP) channels and, 44
- SERCA (sarco/endoplasmic reticulum  $\text{Ca}^{2+}$  ATPase)
  - cardiac myocytes, 410–412, 415, 416
  - pumping mechanism, 231
  - regulators, 233–238
    - antiapoptotic proteins Hax-1 and Bcl-2, 236
    - calumenin, 237–238
    - histidine-rich  $\text{Ca}^{2+}$ -binding protein, 238
    - luminal proteins (calreticulin, calnexin, ERp57), 236–237
  - overview, 233
  - phospholamban, 233–236
  - sarcolipin, 233–236
- SERCA1, 238–239
- SERCA2
  - physiological role of, 230–231
  - regulators, 233–238
  - splicing variants, 230
  - structure of SERCA2b pump, 231–233
- SERCA3, 239–240
- virus infections and, 474
- Signaling pathways, regulation by adenylyl cyclases, 273–290
- Signal transduction, by voltage-gated calcium channels, 2
- Skeletal muscle
  - diseases, 475
  - functional roles of STIM and Orai in, 71
  - visualization of  $\text{Ca}^{2+}$  signaling during embryonic formation in vertebrates, 351–366
    - $\text{Ca}^{2+}$  transients in mouse and rat myotubules, 355–359
  - cultured *Xenopus* myocytes, 363–366
  - examples of developing muscle systems, 353
  - imaging methodologies, 352–355
  - zebrafish embryos, 359–363
- Skin disease, 475–476
- Smooth muscle
  - calcium signaling, 423–438
    - $\text{Ca}^{2+}$  flashes, 427–428, 429, 436
    - $\text{Ca}^{2+}$  sparklets, 428, 430
    - $\text{Ca}^{2+}$  sparks, 432–433, 436
    - $\text{Ca}^{2+}$  waves, 433–435, 436
  - contractility and, 435–437
  - excitation-transcription coupling, 437
  - global  $\text{Ca}^{2+}$  signals, 427, 428, 435–436, 437
  - imaging intracellular  $\text{Ca}^{2+}$ , 424–426
  - intracellular  $\text{Ca}^{2+}$  stores, 431–435
  - $\text{IP}_3\text{R}$  mediated, 433–435
  - nonselective cation channels, 429–431
  - ryanodine receptor (RyR) mediated, 432–433, 436
  - store-operated calcium channels, 429
  - transcription factor activation, 437–438
  - VDCCs, signals mediated by, 426–428, 435–438
  - voltage-gated calcium channels, 426–428
    - described, 423
- SNARE proteins, 13, 255
- SOCs. *See* Store-operated calcium channels (SOCs)
- Sodium/calcium exchanger (NCX)
  - cardiac myocytes, 404, 411, 413–414
  - genetic manipulations, 223
  - isoforms and tissue distribution, 221–222
  - overview, 213–215
  - protein kinase C (PKC) and, 305
  - role in physiology and pathology, 222–223
  - structural and regulatory characteristics, 219–221
- Sodium/proton exchangers (NHE), phosphorylation of, 306
- SPCA (secretory pathway  $\text{Ca}^{2+}$  ATPase), 240–244
  - expression pattern, 240–243
    - SPCA1, 240–242
    - SPCA2, 242–243
  - history of, 240
  - role in cellular physiology, 243–244
    - human disease, 244
    - PMR1 mutants in yeast, 243
  - studies in cell systems, 243
  - studies in model organisms, 243–244
  - structure, 240
- Staurosporine, apoptosis regulation by, 448
- STIM
  - calcium oscillations and, 168–169
  - calcium signaling in smooth muscle, 429
  - functional roles of, 69–71
    - immune cells, 70
    - platelets, 70–71
    - skeletal muscle, 71
    - sweat glands and teeth, 71
  - molecular basis for store-operated calcium entry, 59–69
    - accumulation at ER-PM junctions, 63–64
    - functional organization of, 61
    - oligomerization, 61–63
  - STIM1 roles in calcium channel regulation, 73–74
    - ARC channels, 74
    - TRPC channels, 73–74
    - voltage-gated ( $\text{Ca}_v$ ) channels, 74
  - stoichiometry questions, 66–67
- Store-operated calcium channels (SOCs), 57–75
  - calcium oscillations, 168–171
  - calcium signaling in smooth muscle, 429
  - CRAC channel properties, 68–69
    - $\text{Ca}^{2+}$ -dependent inactivation (CDI), 68–69
  - ion selectivity and permeation, 68

## Index

- Store-operated calcium channels (SOCs) (*Continued*)  
described, 57–59  
ER-PM junctions  
CRAR channel accumulation/activation at, 64–66  
formation and function of, 71–72  
STIM accumulation at, 63–64  
functional roles of STIM and Orai, 69–71  
immune cells, 70  
platelets, 70–71  
skeletal muscle, 71  
sweat glands and teeth, 71  
molecular basis, 59–69  
CRAC channel accumulation/activation at  
ER-PM junctions, 64–66  
CRAC channel properties, 68–69  
functional organization of Orai, 62  
functional organization of STIM, 61  
molecular choreography of calcium entry, 59–61  
oligomerization of STIM, 61–63  
STIM accumulation at ER-PM junctions, 63–64  
stoichiometry questions, 66–67  
regulation of calcium entry in physiological context, 72–73  
STIM1 roles in regulation, 73–74  
ARC channels, 74  
TRPC channels, 73–74  
voltage-gated ( $Ca_V$ ) channels, 74  
Sweat glands, functional roles of STIM and Orai in, 71  
Synapse-to-nucleus communication, calcium signaling in, 371–392  
endoplasmic reticulum as conduit, 390–391  
epigenetic mechanisms in synaptic activity and  $Ca^{2+}$ -dependent transcriptional regulation, 385–387  
extrasynaptic NMDA receptor antagonism, 381–382, 383  
global functional consequences of local signaling, 376–378  
mobile second messengers, 378–381  
nuclear  $Ca^{2+}$  signaling, 382, 384–385, 388–390  
nuclear pore permeability, 387  
overview, 371–376  
Synaptic transmission, metabotropic glutamate receptor type 1 (mGluR1) and, 81–92  
Synaptic vesicle, transient receptor potential (TRP) channels and, 44  
Synaptotagmins, neurotransmitter release and, 254–255
- T**
- T cells  
activation and autophagy, 454  
apoptosis and, 443–447, 449, 451–452
- Teeth, functional roles of STIM and Orai in, 71  
Testosterone, apoptosis regulation by, 446–447  
Thapsigargin, apoptosis regulation by, 448  
Total internal reflection fluorescence (TIRF)  
imaging calcium signaling in smooth muscle, 425–426  
imaging cPKC dynamics in living cells, 300–301  
Transcription factor activation, by calcium signaling in smooth muscle, 437–438  
Transient receptor potential (TRP) channels, 25–45  
 $Ca^{2+}$  permeable TRP pores, 27–29  
change in inwardly-driving forces for  $Ca^{2+}$  entry, 35–38  
depolarization action, 35–38  
described, 25–27  
as intracellular calcium-release channels, 38–44  
endoplasmic reticulum, 38–41  
endosomes, 41–44  
lysosomes, 41–44  
sarcoplasmic reticulum, 38–41  
secretory granules, 44  
secretory vesicles, 44  
synaptic vesicle, 44  
phylogenetic tree of superfamily, 26  
protein kinase C (PKC) and, 304–305  
in smooth muscle cells, 431  
TRPA (ankyrin) family, 34–35  
TRPC (canonical) family, 29–32  
metabotropic glutamate receptor type 1 (mGluR1), 86–92  
STIM1 roles in regulation, 73–74  
TRPC1, 30  
TRPC2, 30  
TRPC3, 31  
TRPC4, 31  
TRPC5, 31  
TRPC6, 31  
TRPC7, 31–32  
TRPM (melastatin) family, 33–34  
TRPM1, 33  
TRPM2, 33–34  
TRPM3, 34  
TRPM4, 34  
TRPM5, 34  
TRPM6, 34  
TRPM7, 34  
TRPM8, 34  
TRPM (mucolipin) family, 35  
TRPP (polycystin) family, 35  
TRPV (vanilloid) family, 32–33  
TRPV1, 32  
TRPV2, 32  
TRPV3, 32–33  
TRPV4, 33  
TRPV5, 33  
TRPV6, 33

Transmissible spongiform encephalopathies, 471–472  
Troponins, 409–410  
TRP. *See* Transient receptor potential (TRP) channels  
Two-pore channels  
  described, 147  
  as NAADP receptors, 147–148  
  phylogenetic tree, 147  
  properties of endogenous from sea urchin eggs,  
    148–149  
  single-channel properties of human, 149–150

## V

Vascular disease, in diabetes mellitus, 469–470  
Virus infection, 473–474  
Voltage-gated calcium channels, 1–17  
  Ca<sup>2+</sup> current types, 2–4  
  calcium oscillation computational models, 162  
  calcium signaling in cardiac myocytes, 404–407,  
    413, 414  
  calcium signaling in smooth muscle, 426–428,  
    435–438  
  Ca<sub>v</sub>1 channels  
    excitation-contraction coupling, 8–11  
    excitation-response coupling, 8  
    excitation-secretion coupling, 12  
    excitation-transcription coupling, 11–12  
  Ca<sub>v</sub>2 channels in synaptic transmission, 12–15  
    Ca<sup>2+</sup> binding proteins, 14–15  
    G protein modulation, 13–14  
    SNARE proteins, 13

Ca<sub>v</sub>3 channels, 15–16  
  functional roles, 16  
  molecular properties, 15–16  
  regulation of, 16  
effector checkpoint model of regulation,  
  16–17  
excitation-contraction coupling, 8–11  
  Ca<sup>2+</sup> binding proteins, 11  
  mechanisms, 8  
  proteolytic processing and regulation via  
    carboxy-terminal domain, 9–10  
  regulation, 8–9  
molecular properties, 4–8  
  channel diversity, 7  
  functions of Ca<sup>2+</sup> channel subunits, 6–7  
  molecular basis of function, 7–8  
  subunit structure, 4–5  
  three-dimensional structure, 5–6  
physiological roles, 1–2  
RyR regulation, 104–105  
STIM1 roles in regulation, 74

## X

*Xenopus* myocytes, visualization of Ca<sup>2+</sup> transients in,  
  363–366

## Z

Zebrafish embryos, Ca<sup>2+</sup> signaling during muscle  
  formation, 359–363